Cargando…

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?

Detalles Bibliográficos
Autor principal:	Deacon, Carolyn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425414/ https://www.ncbi.nlm.nih.gov/pubmed/22923648 http://dx.doi.org/10.2337/db12-0649

Ejemplares similares

Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
por: Salehi, Marzieh, et al.
Publicado: (2010)

Is endogenous GLP-1 a major influence on the orbitofrontal cortex?
por: May, Aaron A., et al.
Publicado: (2015)

Hypothalamic Regulation of Glucose-Stimulated Insulin Secretion
por: Chan, Owen, et al.
Publicado: (2012)

BLX‐1002 restores glucose sensitivity and enhances insulin secretion stimulated by GLP‐1 and sulfonylurea in type 2 diabetic pancreatic islets
por: Zhang, Qimin, et al.
Publicado: (2014)

Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes
por: Jalleh, Ryan J, et al.
Publicado: (2022)

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
por: Woerle, Hans Juergen, et al.
Publicado: (2012)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
por: ten Kulve, Jennifer S., et al.
Publicado: (2015)

Is insulin an endogenous cardioprotector?
por: Das, Undurti N
Publicado: (2002)

Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes?
por: Wahren, John, et al.
Publicado: (2012)

Hypothalamic AMP-activated Kinase Regulates Glucose-stimulated Insulin Secretion
por: Koh, Eun Hee, et al.
Publicado: (2016)

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin
por: Jones, Angus G, et al.
Publicado: (2012)

Systematic Synergy of Glucose and GLP-1 to Stimulate Insulin Secretion Revealed by Quantitative Phosphoproteomics
por: Tang, Jia-shu, et al.
Publicado: (2017)

Metformin induces insulin secretion by preserving pancreatic aquaporin 7 expression in type 2 diabetes mellitus
por: Kimura, Tomohiko, et al.
Publicado: (2021)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
por: D'Alessio, David A.
Publicado: (2010)

Delineating the transcriptional atlas for impaired insulin secretion: A window into type 2 diabetes pathophysiology
por: Li, Jian, et al.
Publicado: (2023)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism
por: Medak, Kyle D., et al.
Publicado: (2023)

Continuity of care: important, but only the first step
por: Corrigan, Janet M
Publicado: (2012)

Residual endogenous insulin secretion in Japanese children with type 1A diabetes
por: Sugihara, Shigetaka, et al.
Publicado: (2021)

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence
por: Meloni, A R, et al.
Publicado: (2013)

Hyperglycemia in the intensive care unit: is insulin the only option?
por: Dungan, Kathleen M
Publicado: (2013)

DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity
por: Böhm, Anja, et al.
Publicado: (2017)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring
por: Miya, Aika, et al.
Publicado: (2021)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion
por: Ahlkvist, L, et al.
Publicado: (2013)

GLUT12: a second insulin‐responsive glucose transporters as an emerging target for type 2 diabetes
por: Matsuzaka, Takashi, et al.
Publicado: (2011)

The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model
por: Røge, RM, et al.
Publicado: (2015)

Effects of Type 2 Diabetes on Insulin Secretion, Insulin Action, Glucose Effectiveness, and Postprandial Glucose Metabolism
por: Basu, Ananda, et al.
Publicado: (2009)

Differential Stimulation of Insulin Secretion by GLP-1 and Kisspeptin-10
por: Schwetz, Tara A., et al.
Publicado: (2014)

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity
por: Kozawa, Junji, et al.
Publicado: (2012)

Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes
por: Menge, Björn A., et al.
Publicado: (2011)

Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21?
por: Liu, Jun-Li, et al.
Publicado: (2019)

Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes
por: Shibasaki, Saeko, et al.
Publicado: (2010)

Isoprenoid Derivatives of Lysophosphatidylcholines Enhance Insulin and GLP-1 Secretion through Lipid-Binding GPCRs
por: Drzazga, Anna, et al.
Publicado: (2021)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p6o4p6medou897rq0d8p4ttedv